Menú Close

Artículos sobre A-beta

Mostrando todos artículos

Do the benefits of approving a drug before confirming it works outweigh the potential costs? monkeybusinessimages/iStock via Getty Images Plus

The FDA’s big gamble on the new Alzheimer’s drug

The FDA approved Alzheimer's disease drug aducanumab despite minimal evidence of its efficacy. Whether this decision ultimately hurts or helps patients depends on data researchers don't yet have.
In most cases, scientists are still unsure of what causes Alzheimer’s disease. FGC / Shutterstock.com

No cure for Alzheimer’s disease in my lifetime

After the failure of multiple drug trials the outlook for an Alzheimer's drug is bleak. This shouldn't be a surprise. We don't know the cause or even how to diagnose the disease.
An MRI image of the brain. SpeedKingz/Shutterstock.com

An unexpected pathway to treating neurodegenerative diseases

Not all drug development needs to start from scratch. Sometimes researchers discover that a drug developed for one disease can be used for another. Here a cancer drug may show promise for dementia.
Figuring out the pieces to the Alzheimer’s puzzle. Naeblys/Shutterstock.com

Time for a Manhattan Project on Alzheimer’s

Many pieces leading to Alzheimer's disease have been identified. To put the pieces together, one scholar argues that the government should launch a Manhattan Project-scale effort to find a cure.

Principales colaboradores